These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11130122)

  • 1. [Methotrexate].
    Schröder F; Schroeder JO
    Dtsch Med Wochenschr; 2000 Nov; 125(47):1435-6. PubMed ID: 11130122
    [No Abstract]   [Full Text] [Related]  

  • 2. The molecular perspective: methotrexate.
    Goodsell DS
    Oncologist; 1999; 4(4):340-1. PubMed ID: 10476546
    [No Abstract]   [Full Text] [Related]  

  • 3. [Methotrexate--mechanism of action and application].
    Dabkowska B; Dabkowski J
    Pol Merkur Lekarski; 2001 Nov; 11(65):452-5. PubMed ID: 11852822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance.
    Ramakers-van Woerden NL; Pieters R; Rots MG; van Zantwijk CH; Noordhuis P; Beverloo HB; Peters GJ; van Wering ER; Camitta BM; Pui CH; Relling MV; Evans WE; Veerman AJ
    Leukemia; 2002 May; 16(5):949-51. PubMed ID: 11986959
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.
    Levy AS; Sather HN; Steinherz PG; Sowers R; La M; Moscow JA; Gaynon PS; Uckun FM; Bertino JR; Gorlick R;
    J Pediatr Hematol Oncol; 2003 Sep; 25(9):688-95. PubMed ID: 12972803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).
    Giverhaug T; Loennechen T; Aarbakke J
    Gen Pharmacol; 1999 Oct; 33(4):341-6. PubMed ID: 10523073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical mechanisms of resistance to antimetabolites.
    Harrap KR; Jackson RC
    Antibiot Chemother (1971); 1978; 23():228-37. PubMed ID: 348081
    [No Abstract]   [Full Text] [Related]  

  • 8. [New Indings in Methotrexate Pharmacology -  Diagnostic Possibilities and Impact on Clinical Care].
    Řiháček M; Pilatova K; Štěrba J; Pilný R; Valík D
    Klin Onkol; 2015; 28(3):163-70. PubMed ID: 26062617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities.
    Robinson AD; Eich ML; Varambally S
    Cancer Lett; 2020 Feb; 470():134-140. PubMed ID: 31733288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed elimination of methotrexate in a patient receiving ciprofloxacin.
    Aouinti I; Gaïes E; Trabelsi S; Salouage I; Jebabli N; Charfi R; Lakhal M; Klouz A
    Therapie; 2013; 68(3):175-7. PubMed ID: 23886465
    [No Abstract]   [Full Text] [Related]  

  • 11. Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia. New insights from the lab and clinic.
    Evans WE; Pui CH; Relling MV
    Adv Exp Med Biol; 1999; 457():537-41. PubMed ID: 10500831
    [No Abstract]   [Full Text] [Related]  

  • 12. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia.
    Matherly LH; Taub JW
    Leuk Lymphoma; 1996 May; 21(5-6):359-68. PubMed ID: 9172800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interaction between high-dose methotrexate and oxacillin.
    Titier K; Lagrange F; Péhourcq F; Moore N; Molimard M
    Ther Drug Monit; 2002 Aug; 24(4):570-2. PubMed ID: 12142645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose methotrexate in fibroblastic osteosarcoma.
    Chowbay B; Siong KK
    Ann Pharmacother; 2001 Dec; 35(12):1669. PubMed ID: 11793640
    [No Abstract]   [Full Text] [Related]  

  • 15. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
    Chen G; Wright JE; Rosowsky A
    Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular perspective: methotrexate.
    Goodsell DS
    Stem Cells; 1999; 17(5):314-5. PubMed ID: 10527466
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and preliminary in vitro screening of lipophilic alpha, gamma-bis(amides) as potential prodrugs of methotrexate.
    Pignatello R; Sorrenti V; Spampinato G; Pecora T; Panico A; Di Giacomo C; Fresta M; Vanella A; Puglisi G
    Anticancer Drug Des; 1996 Apr; 11(3):253-64. PubMed ID: 8663912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of plasma total homocysteine in patients receiving high-dose methotrexate therapy.
    Guttormsen AB; Ueland PM; Lønning PE; Mella O; Refsum H
    Clin Chem; 1998 Sep; 44(9):1987-9. PubMed ID: 9732989
    [No Abstract]   [Full Text] [Related]  

  • 19. Methotrexate.
    Held-Warmkessel J
    Clin J Oncol Nurs; 2000; 4(4):187-8. PubMed ID: 11261104
    [No Abstract]   [Full Text] [Related]  

  • 20. DNA synthesis as a therapeutic target: the first 65 years.
    Mathews CK
    FASEB J; 2012 Jun; 26(6):2231-7. PubMed ID: 22653564
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.